U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H5I2NO3.C4H11NO2
Molecular Weight 510.0641
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IODOPYRACET

SMILES

OCCNCCO.OC(=O)CN1C=C(I)C(=O)C(I)=C1

InChI

InChIKey=RERHJVNYJKZHLJ-UHFFFAOYSA-N
InChI=1S/C7H5I2NO3.C4H11NO2/c8-4-1-10(3-6(11)12)2-5(9)7(4)13;6-3-1-5-2-4-7/h1-2H,3H2,(H,11,12);5-7H,1-4H2

HIDE SMILES / InChI

Molecular Formula C7H5I2NO3
Molecular Weight 404.9284
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H11NO2
Molecular Weight 105.1356
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Iodopyracet (Diodone) is a radiocontrast agent used in urography before 1950. Renal clearance of iodopyracet is characterized by supply-limited elimination at low plasma concentrations and capacity-limited elimination at high plasma levels. Iodopyracet to be an effective agent for the estimation of renal plasma flow and tubular function has been used extensively in physiological studies. In 1945 was found, that p-aminohippuric acid was in some ways superior to diodone for these estimations in man because the urine and plasma blanks are small and because diodone penetrates human red blood cells whereas p-aminohippuric acid does not.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
3.0 g, administered i.v.
Route of Administration: Intravenous
Substance Class Chemical
Record UNII
ZTK4026YJ5
Record Status Validated (UNII)
Record Version